Biogen vs Moderna
BIIB and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIIB and MRNA compare
Moderna is the larger company, worth 2.4 times as much as Biogen ($88.5B against $37.5B).
Biogen grew revenue faster over the last twelve months (0.31% versus −27.6% for Moderna).
Biogen keeps more of each dollar of sales as profit, with a net margin of 8.3% compared with −141% at Moderna.
Moderna scores higher on the StockData Score (5 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIIB | MRNA |
|---|---|---|
| Size and price | ||
| Market cap | $37.5B | $88.5B |
| Share price | $253.62 | $221.72 |
| Change, 1 year | 71.5% | 798% |
| Change, 5 years | −9.0% | −6.4% |
| Beta (5Y) | 0.51 | 1.11 |
| Employees | 7,500 | 4,700 |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 44.9× | – |
| P/S | 3.7× (better) | 39.7× |
| P/B | – | 13.1× |
| EV/EBITDA | 16.9× | – |
| P/FCF | 13.9× | – |
| FCF yield | 7.2% (better) | −1.4% |
| Fair value | $157.62 | $33.24 |
| Margin of safety | −60.9% (better) | −567% |
| Growth | ||
| Revenue growth (TTM) | 0.31% (better) | −27.6% |
| Revenue growth, 5Y average | −6.0% | 19.3% (better) |
| Net income growth (TTM) | −45.5% | – |
| EPS growth (TTM) | −46.0% | – |
| EPS growth, 5Y average | −18.7% | – |
| Profitability | ||
| Gross margin | 74.0% (better) | 23.4% |
| Operating margin | – | −149% |
| Net margin | 8.3% (better) | −141% |
| FCF margin | 26.9% (better) | −55.8% |
| Return on equity | – | −39.0% |
| Return on invested capital | – | −80.9% |
| Financial health | ||
| Debt / equity | – | 0.09 |
| Current ratio | 1.87 | 2.29 (better) |
| Altman Z-score | 3.05 | 12.86 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 96.3% | 79.9% |
| Held by insiders | 0.21% | 5.6% |
| Insider net buying, 12 months | −$905K (better) | −$64.6M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.0% | 8.2% |
Go deeper
- BIIB stock overview
- BIIB income statement
- BIIB valuation and score
- MRNA stock overview
- MRNA income statement
- MRNA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.